Kolexia
Cortot Alexis Pneumologie
Cortot Alexis
Pneumologie
Hôpital Albert Calmette
Lille, France
431 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du poumon Carcinome pulmonaire non à petites cellules Carcinome pulmonaire à petites cellules Adénocarcinome Métastase tumorale Carcinomes Adénocarcinome pulmonaire Tumeurs du cerveau Mésothéliome

Collaborateurs

Voir plus
Mazieres Julien
Mazieres Julien
Hôpital Rangueil, Toulouse, France
Girard Nicolas
Girard Nicolas
Clcc Institut Curie, Paris, France
Moro-Sibilot Denis
Moro-Sibilot Denis
Hôpital Nord Grenoble, La Tronche, France
Scherpereel Arnaud
Scherpereel Arnaud
Hôpital Albert Calmette, Lille, France

Industries

Voir plus
A+A
22 collaboration(s)
Dernière en 2020
Novartis
21 collaboration(s)
Dernière en 2023
Pfizer
15 collaboration(s)
Dernière en 2023
AstraZeneca
14 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours: A Phase 1 Study to Determine the Safety, and Pharmacokinetics of the Selective MET Kinase Inhibitor, DO-2 in Patients With Advanced or Refractory Solid Tumours
Essai Clinique (DeuterOncology)   13 mars 2024
ROSIE: A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)
Essai Clinique (Intergroupe Francophone de Cancérologie Thoracique)   06 mars 2024
Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK): A Phase II Randomized, Open-Labelled, Multicenter Study of Safety & Efficacy of Combination Brigatinib and Carboplatin-Pemetrexed Therapy or Brigatinib Monotherapy as First-Line Treatment in Advanced ALK-Positive Non-Small Cell Lung Cancer
Essai Clinique (Intergroupe Francophone de Cancérologie Thoracique)   06 mars 2024
SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression
Essai Clinique (Lilly)   27 février 2024
MELROSE: Phase 2 Study Evaluating MEchanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtinib Until and Beyond Radiological Progression : the MELROSE Trial
Essai Clinique (AstraZeneca)   26 février 2024
AcSé CRIZOTINIB : Secured Access to Crizotinib for Patients With Tumors Harboring a Genomic Alteration on One of the Biological Targets of the Drug.
Essai Clinique (Unicancer)   26 février 2024
Met Non Small Cell Cancer Registry (MOMENT): Disease Registry on Patients With Advanced NSCLC Harboring METex14 Skipping Alterations (MOMENT)
Essai Clinique (Emd Serono)   19 février 2024
Profiles, diagnostic process, and patterns of care of patients with stage III non-small cell lung cancer: A French national study
Respiratory medicine and research   23 janvier 2024
LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer: A Phase III Multicenter, Randomized Study of Oral LDK378 Versus Standard Chemotherapy in Previously Untreated Adult Patients With ALK Rearranged (ALK-positive), Stage IIIB or IV, Non-squamous Non-small Cell Lung Cancer
Essai Clinique (Novartis)   22 janvier 2024
JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy
Essai Clinique (Lilly)   18 janvier 2024